After Allergan (NYSE: AGN) chief executive Brent Saunders pledged to limit price increases to single digits, three pharmaceutical companies agreed to make the same commitment, according to Public Citizen.
The companies are AbbVie (NYSE: ABBV), Novo Nordisk (NOV: N) and Valeant Pharmaceuticals (TSX: VRX).
Although it was reported that Takeda Pharmaceutical (TYO: 4502) would also follow suit, CEO Christophe Weber’s comment that the firm is “very committed” to the single-digit goal surely leaves some wriggle room.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze